Trial Profile
A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone; Doxorubicin; Melphalan; Stem cell therapies
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GMMG-HD7
- 12 Nov 2023 Results (n=179) assessing the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection from GMMG-HD6 (NCT02495922) and GMMG-HD7 (NCT03617731) trials, published in the BMC Cancer.
- 14 Dec 2021 Primary endpoint has been met. (MRD negativity after induction Treatment (comparison of arms IA and IB), as per Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition